FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
notruction 1/h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* MORGENSTERN VICTOR A (Last) (First) (Middle)				BIG	2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC [BPA]										ationship of Repo call applicable) Director Officer (give til below)		10 ⁹ Oth	o Issuer % Owner er (specify ow)		
106 VIN	INE AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 04/08/2004														
(Street) HIGHLAND PARK IL 60035					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(St	ate) (Zip)																	
		Tabl	e I - N	on-Deriv	ative	Sec	uritie	s Ac	quired	d, Di	sposed o	f, or B	enefi	cia	lly Own	ed				
Da		Date	Transaction te onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a 5)				Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	Amount	(A) or (D)	Price	9	Reported Transacti (Instr. 3 a	tion(s)			(instr. 4)						
Common Stock		04/08/2004				A		87(1)	A	\$0	(2)	396,419			D					
Common Stock												283,281		I		By Morningstar Trust ⁽³⁾				
Common	Stock														63,281			I	By Resolute Partners ⁽⁴⁾	
Common	Stock														70,0	By spouse				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, Transaction or Exercise (Month/Day/Year) if any Code (Instr					5. Nui of Derivi Secui Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired osed	6. Date Expirat (Month	ion Da		Amount of Securities Underlying Derivative Security (Instr. and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)		
				Codo				Date Evereisable		Expiration	Numbe of Shares		.							

Explanation of Responses:

- 1. Mr. Morgenstern acquired these shares as a stock award for director compensation granted under BioSante Pharmaceutical's Amended and Restated 1998 Stock Plan.
- 3. Held by Morningstar Trust to which Mr. Morgenstern's wife is a trustee. Mr. Morgenstern disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- 4. Held by Resolute Partners to which Mr. Morgenstern is a managing director.

/s/ Victor Morgenstern, by Phillip B. Donenberg, attorney- 04/14/2004 in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.